Explore the new TDD supplement for the latest thinking on treating transitional skin, including adult acne and the signs of pre-aging. thedermdigest.com
The Dermatology Digest
Book and Periodical Publishing
Actionable print and digital content for practicing dermatologists, dermatologic surgeons, and skincare professionals.
About us
The Dermatology Digest provides actionable print and digital content for practicing dermatologists, dermatologic surgeons, and skincare professionals. The publication offers exclusive, front-row access to top-tier dermatology conferences, allowing readers to apply what they learn from the podium to their practice. Published quarterly, the print edition distills cutting-edge learning into digestible and timely, practice-enhancing information. Coverage areas include clinical practice, regulatory news and updates, practice management tips, and new products. Our primary goal is educating for improved patient outcomes.
- Website
-
https://thedermdigest.com/
External link for The Dermatology Digest
- Industry
- Book and Periodical Publishing
- Company size
- 11-50 employees
- Type
- Privately Held
- Founded
- 2023
Employees at The Dermatology Digest
Updates
-
Organon is acquiring Dermavant Sciences Ltd. Dermavant’s novel product, tapinarof cream, 1% (Vtama) for the topical treatment of mild, moderate, and severe plaque psoriasis in adults, was approved by the U.S. FDA in May 2022. The FDA is reviewing a Supplemental New Drug Application (sNDA) for tapinarof cream, 1% as a potential treatment for atopic dermatitis (AD) in adults and children two years of age and older, with Prescription Drug User Fee Act (PDUFA) action expected in the fourth quarter of calendar year 2024. https://lnkd.in/dqBFizFN
-
JACQUELINE WATCHMAKER, MD, a dermatologist in Scottsdale, AZ, pays homage to everyone’s favorite anti-ager as part of the first-ever National Retinoid Week. She also shares some of her favorite retinoids. skinbetter science launched #RetinoidWeek. https://lnkd.in/d5cshtrk
Celebrate #RetinoidWeek With Dr. Jacqueline Watchmaker - The Dermatology Digest
https://thedermdigest.com
-
One in four people with psoriasis may show early signs of psoriatic arthritis, according to initial results from the Hippocrates Prospective Observational Study (HPOS). The study is conducted by researchers at University College Dublin in partnership with the University of Oxford and aims to monitor people with psoriasis to see if psoriatic arthritis can be spotted and treated earlier. So far, approximately 1,500 participants have registered and completed an online evaluation tool. https://lnkd.in/dt84cwv2
One in Four Psoriasis Patients Show Signs of Psoriatic Arthritis - The Dermatology Digest
https://thedermdigest.com
-
About half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to follow-up data from CheckMate -067 presented at the ESMO - European Society for Medical Oncology Congress 2024 in Barcelona, Spain and simultaneously published in The New England Journal of Medicine. https://lnkd.in/dsXRhnkv Jedd Wolchok, MD, PhD
“Practice-changing” Results: Long-term Advanced Melanoma Survival Dramatically Improves on Immunotherapy - The Dermatology Digest
https://thedermdigest.com
-
Joel M Gelfand MD MSCE, Carol Ostrow, and Jose U. Scher, MD, will be honored at The National Psoriasis Foundation 2025 Commit to Cure Gala in New York City. https://lnkd.in/d2K2Bv-b
Meet the 2025 National Psoriasis Foundation Commit to Cure Gala Honorees - The Dermatology Digest
https://thedermdigest.com
-
The U.S. FDA has approved lebrikizumab-lbkz (Ebglyss, Lilly), a targeted interleukin (IL)-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40kg) with moderate-to-severe #atopicdermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies. https://lnkd.in/d4QMGNMj
BREAKING NEWS: U.S. FDA Approves Lilly’s Ebglyss (Lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe AD - The Dermatology Digest
https://thedermdigest.com
-
Steve Clark, 81, passed away on September 8, 2024. He served as the President of Galderma Laboratories from 1985-2001, making it one of the most successful #dermatology companies in the world by acquiring, developing, and launching notable products such as MetroGel, Differen Triluma, Desowen, Benzac, and the Cetaphil product line, among others. In 2003, after retiring from Galderma, Mr. Clark became the President of Coria Laboratories, which was a launchpad for Cerave skincare. https://lnkd.in/dPkNb9mt Suzanne Lane
In Memoriam: Dermatology Community Mourns the Loss of Stephen W. Clark - The Dermatology Digest
https://thedermdigest.com
-
In the Level Up study, upadacitinib (Rinvoq, AbbVie) bested dupilumab (Dupixent, Regeneron and Sanofi) in the primary endpoint, demonstrating that a significantly higher proportion of #atopicdermatitis (AD)patients simultaneously achieved both a 90% or greater reduction in Eczema Area and Severity Index (EASI 90) and a Worst Pruritus Numerical Rating Scale of 0 or 1(WP-NRS 0/1) at Week 16. Level-Up Investigator Christopher Bunick, MD, PhD, an Associate Professor of Dermatology at Yale University in New Haven, CT, reviews the data and explains how these findings help elevate the standard of care in AD. https://lnkd.in/ddBBvyDK
Raising the Bar in Atopic Dermatitis: Unpacking the practice-changing implications of the LEVEL UP study in AD - The Dermatology Digest
https://thedermdigest.com
-
Leading #dermatologists and facial plastic surgeons are sounding the alarm about a perilous social media trend: self-injections with unapproved soft tissue fillers. Growing numbers of consumers are purchasing unapproved soft tissue fillers online and injecting their own lips, cheeks, and under-eye hollows. Many videos feature non-experts describing DIY injection techniques while glossing over or ignoring such risks as bruising, redness, swelling, skin and soft tissue infections, tissue death, and even blindness. https://lnkd.in/dUnqh92J
TDD Investigates the Risky Business of Self-Injection of Unapproved Fillers - The Dermatology Digest
https://thedermdigest.com